About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNANCT04266327

RISI in the Treatment of Recurrent Metastatic SCC of Thoracic Inlet Lymph Nodes

The malignant tumor at the thoracic entrance is difficult to be surgically removed, and radiotherapy or radiotherapy based comprehensive treatment is often chosen at the initial diagnosis. However, fo...

Lead sponsor: Peking University Third Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Zhe Ji, M.D.

CONTACT

008618710002823 aschoff@163.com

Sponsors

Lead Sponsor

Peking University Third Hospital

This is a non-randomized, prospective, single-arm, cohort study.Patients meeting the inclusion criteria were enrolled successively in the order of admission and treatment.In this study, the dose interval was set as 110-130gy, and a total of 30 patients were expected to be enrolled. The prescription dose was planned to be grouped into 15 patients of 110-120gy and 120-130gy respectively. The specific situation was subject to the actual postoperative verification dose.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•(1) age 18-75 years
•(2) the lesion was located at the thoracic entrance, pathologically diagnosed as lymph node metastatic squamous cell carcinoma, and relapsed after radiotherapy. The diameter of the lesion was ≤5cm
•(3) no systemic metastasis or metastasis, the metastasis has been controlled by early treatment
•(4) no bleeding tendency, anticoagulant treatment and (or) anti-platelet coagulation drugs should be at least 1 week before the seed implantation treatment
•(5) not complicated with serious or uncontrolled basic diseases (such as serious or uncontrolled hypertension, diabetes, cardiovascular and cerebrovascular diseases and organ dysfunction, etc.)
•(6) there is a suitable puncture path, is expected to reach the treatment dose;7 KPS\> score of 70, expected to be able to tolerate puncture/particle therapy, the expected survival time is more than 3 months

Exclusion Criteria

•(1) extensive invasion of the lesion or surrounding of large blood vessels or large scope of liquefaction necrosis inside the lesion, high risk of expected puncture bleeding or poor particle distribution
•(2) puncture site infection and/or ulcer
•(3) pregnant women, nursing women, children and mental patients
•(4) patients who are participating in other clinical studies
•(5) poor compliance, unable to complete the treatment
•(6) the researchers consider it inappropriate to participate in the clinical trial

Related studies

RECRUITINGPhase 2

Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies

NCT05979610 · Gynecologic Neoplasm, Brachytherapy, and more

RECRUITINGPhase 2/3

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

NCT07426094 · Prostate Cancer, Brachytherapy, and more

Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

NCT07131956 · Prostate Cancer (Diagnosis), Prostate Cancer Patients Who Have Brachytherapy Seed Implant, and more

RECRUITINGPhase 1

A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

NCT06469008 · Head and Neck Squamous Cell Carcinomas, Solid Tumor

RECRUITINGPhase 2

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

NCT05894018 · Sarcoma,Soft Tissue, Brachytherapy, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 27, 2023Terms

Trial snapshot

StatusUNKNOWN

PhaseNA

Enrollment30

Start dateMay 2020

Last updatedDec 27, 2023

Condition

Brachytherapy Squamous Cell Carcinomas

Locations shown

Peking University Third Hospital

Beijing, Beijing Municipality

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 27, 2023Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions